biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Chrispi’s response

<< Previous

Bullboard Posts

Next >>

Post by ronrydellon Dec 17, 2021 1:00pm

140 Views

Post# 34241206

Chrispi’s response

I should have included PEG's.....agreed that that strategics will buy but most announcements that I have seen have had completed trials...I, II, and III. ALTHOUGH if we get the long waited NR's that are great a pre trials deal could be done at a very low price. Hopefully that might happen...I'll look forward to discussing this with the investment bank that Deborah signed up with yesterday

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023